Gobburu JV - Search Results

1

Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.

Jang SH, Colangelo PM, Gobburu JV. Jang SH, et al. Among authors: gobburu jv. Clin Pharmacol Ther. 2010 Jul;88(1):115-9. doi: 10.1038/clpt.2010.64. Epub 2010 May 26. Clin Pharmacol Ther. 2010. PMID: 20505665 Clinical Trial.

2

Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal E_max regressions.

Beumer JH, Kennard BC, Holleran JL, Moore N, Zlott J, Miller BM, Kummar S, Chen A, Doroshow J, Park W, Gobburu J, Dunn A. Beumer JH, et al. Cancer Chemother Pharmacol. 2023 Mar;91(3):219-230. doi: 10.1007/s00280-023-04509-8. Epub 2023 Feb 23. Cancer Chemother Pharmacol. 2023. PMID: 36813886 Free PMC article.

3

Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.

Gobburu JV, Tammara V, Lesko L, Jhee SS, Sramek JJ, Cutler NR, Yuan R. Gobburu JV, et al. J Clin Pharmacol. 2001 Oct;41(10):1082-90. doi: 10.1177/00912700122012689. J Clin Pharmacol. 2001. PMID: 11583476 Clinical Trial.

4

Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application.

Gobburu JV, Sekar VJ. Gobburu JV, et al. Int J Clin Pharmacol Ther. 2002 Jul;40(7):281-8. doi: 10.5414/cpp40281. Int J Clin Pharmacol Ther. 2002. PMID: 12139204

5

Considerations in analyzing single-trough concentrations using mixed-effects modeling.

Booth BP, Gobburu JV. Booth BP, et al. Among authors: gobburu jv. J Clin Pharmacol. 2003 Dec;43(12):1307-15. doi: 10.1177/0091270003258670. J Clin Pharmacol. 2003. PMID: 14615466

6

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV. Ramchandani RP, et al. Among authors: gobburu jv. J Clin Pharmacol. 2007 Jan;47(1):78-86. doi: 10.1177/0091270006295060. J Clin Pharmacol. 2007. PMID: 17192505

7

Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.

Booth BP, Rahman A, Dagher R, Griebel D, Lennon S, Fuller D, Sahajwalla C, Mehta M, Gobburu JV. Booth BP, et al. Among authors: gobburu jv. J Clin Pharmacol. 2007 Jan;47(1):101-11. doi: 10.1177/0091270006295789. J Clin Pharmacol. 2007. PMID: 17192508 Clinical Trial.

8

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

Bhattaram VA, Bonapace C, Chilukuri DM, Duan JZ, Garnett C, Gobburu JV, Jang SH, Kenna L, Lesko LJ, Madabushi R, Men Y, Powell JR, Qiu W, Ramchandani RP, Tornoe CW, Wang Y, Zheng JJ. Bhattaram VA, et al. Among authors: gobburu jv. Clin Pharmacol Ther. 2007 Feb;81(2):213-21. doi: 10.1038/sj.clpt.6100051. Clin Pharmacol Ther. 2007. PMID: 17259946

9

Pharmacometrics at FDA: evolution and impact on decisions.

Powell JR, Gobburu JV. Powell JR, et al. Among authors: gobburu jv. Clin Pharmacol Ther. 2007 Jul;82(1):97-102. doi: 10.1038/sj.clpt.6100234. Epub 2007 May 30. Clin Pharmacol Ther. 2007. PMID: 17538553 Review.

10

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Garnett CE, et al. Among authors: gobburu jv. J Clin Pharmacol. 2008 Jan;48(1):13-8. doi: 10.1177/0091270007307881. J Clin Pharmacol. 2008. PMID: 18094216 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144 results

Search Page

Filters